WallStSmart

Avantor Inc (AVTR)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Avantor Inc generates 97% more annual revenue ($6.56B vs $3.33B). WST leads profitability with a 17.0% profit margin vs -8.8%. WST earns a higher WallStSmart Score of 61/100 (C+).

AVTR

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 3.5Value: 6.0Quality: 5.0
Piotroski: 3/9Altman Z: 1.32

WST

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AVTRUndervalued (+23.7%)

Margin of Safety

+23.7%

Fair Value

$12.63

Current Price

$14.81

$2.18 discount

UndervaluedFair: $12.63Overvalued
WSTSignificantly Overvalued (-46.2%)

Margin of Safety

-46.2%

Fair Value

$168.33

Current Price

$346.23

$177.90 premium

UndervaluedFair: $168.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVTR1 strengths · Avg: 8.0/10
Price/BookValuation
1.8x8/10

Reasonable price relative to book value

WST3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Operating MarginProfitability
22.5%8/10

Strong operational efficiency at 22.5%

Areas to Watch

AVTR4 concerns · Avg: 2.8/10
Revenue GrowthGrowth
0.5%4/10

0.5% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-9.9%2/10

ROE of -9.9% — below average capital efficiency

EPS GrowthGrowth
-37.4%2/10

Earnings declined 37.4%

WST3 concerns · Avg: 2.7/10
Price/BookValuation
8.2x4/10

Trading at 8.2x book value

PEG RatioValuation
2.672/10

Expensive relative to growth rate

P/E RatioValuation
43.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : AVTR

The strongest argument for AVTR centers on Price/Book.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : AVTR

The primary concerns for AVTR are Revenue Growth, Piotroski F-Score, Return on Equity.

Bear Case : WST

The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.

Key Dynamics to Monitor

AVTR profiles as a turnaround stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.14 — expect wider price swings.

WST is growing revenue faster at 13.8% — sustainability is the question.

AVTR generates stronger free cash flow (141M), providing more financial flexibility.

Bottom Line

WST scores higher overall (61/100 vs 38/100), backed by strong 17.0% margins and 13.8% revenue growth. AVTR offers better value entry with a 23.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Avantor Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Avantor, Inc. provides products and services to clients in the biopharmaceutical, healthcare, education and government, advanced technologies and applied materials industries in America, Europe, Asia, the Middle East and Africa. The company is headquartered in Radnor, Pennsylvania.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?